Bealach amach 5 an M50, Án Bóthar Thuaidh, Fionnghlas, Baile Átha Cliath 11, D11 XKF3

Guthán: 01 8647100



Primary Care Reimbursement Service Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3 Tel: 01-8647100

Colm Burke, T.D. Dáil Éireann, Leinster House, Kildare Street, Dublin 2.

16th February, 2021

PQ: 7588/21

To ask the Minister for Health if the drug patisiran onpattro which was recently reviewed by the National Centre for Pharmacoeconomics will be available under the drugs payment scheme to those who have been identified as requiring the medication for their care; and if he will make a statement on the matter - Colm Burke.

Dear Deputy Burke,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 7588/21), which you submitted to the Minister for Health for response. The HSE is committed to providing access to as many medicines as possible in as timely a fashion as possible from the resources available (provided) to it.

The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds. There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed.

The HSE received an application for pricing / reimbursement of Patisiran (Onpattro®) from Alnylam (the applicant) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy and the application remains under consideration with the HSE.

Until the product is formally approved for reimbursement support by the HSE, it is not available under any of the statutory Community Drugs Schemes including the Drugs Payment Scheme.

Yours sincerely,

Suzanne Doyle

Primary Care Eligibility & Reimbursement Service